ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, usual dosage and administration, relative contraindications, clinically significant drug intractions and adverse drug reactions of Maprotiline. The risk for seizures may be increased when the recommended dosage of maprotiline is rapidly exceeded. Risk also may be increased when maprotiline pharmacotherapy is prescribed with phenothiazine pharmacotherapy or when the dosage of concurrent benzodiazepine pharmacotherapy is rapidly reduced. Maprotiline appears to produce its antidepressant action primarily by potentiating the CNS biogenic amines, particularly norepinephrine, by blocking their re-uptake at the pre-synaptic nerve terminals. The most common ADRs associated with maprotiline pharmacotherapy are related to its anticholinergic actions. These ADRs include blurred vision, constipation, dry mouth, headache, nervousness, sedation, and vertigo. Signs and symptoms of maprotiline overdosage may vary according to the severity of the overdosage. Generally, signs and symptoms reflect maprotiline’s CNS, anticholinergic, and cardiotoxic actions.
